The industry, patients, and clinicians should now seek a better understanding of the criteria and conditions, including any potential relationship with the health technology assessment review recommendations and any obligation on the company if DFMO does not successfully navigate the reimbursement process.
Worth knowing the criteria used to justify the creation of the DFMO 'bridging' fund
July 16, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
What is it with this organisation's obsession with pharmacy and Europe?
July 13, 2026 - - Latest News -
Mesoblast reports strong cell therapy revenue as first year as uptake grows
July 13, 2026 - - Latest News -
The inevitability of disappointment over a reform process that has devolved into word games
July 12, 2026 - - Latest News -
The 'Dispatched' Podcast - Series 5, Ep 23
July 10, 2026 - - Podcast -
Disruption is the overdue remedy and how this debate can revitalise the PBS
July 10, 2026 - - Latest News -
Melbourne study links higher tumour radiation dose to longer progression-free survival
July 10, 2026 - - Latest News -
Older Australians are underestimating their personal risk from RSV
July 10, 2026 - - Latest News

